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Alterations of both cyclic AMP and calcium metabolism have been 
found in many cell types from patients with cystic fibrosis (CF). Several 
groups have reported an increase in intracellular cyclic AMP in CF 
fibroblasts after stimulation with isoproterenol (1,2). These results have 
been confirmed by Markovac et al. and are reported in the accompanying 
paper (3). Markovac ef al. (3) also found increased specific binding of 
the p-adrenergic ligand, [3H]dihydroalprenolo1, to the CF-cultured fibro- 
blasts, which could partially account for the increased response to p- 
adrenergic agonists found in these cells. Abnormalities in calcium content 
and metabolism have also been detected in cultured skin fibroblasts from 
patients with CF. These cells show increased intracellular calcium pools 
and altered calcium transport across membranes (4,5). The abnormalities 
in both calcium and cyclic AMP found in CF-cultured skin fibroblasts 
suggest the possible involvement of calmodulin, an endogenous calcium- 
binding protein. Calmodulin has been found to affect many calcium- 
dependent activities as well as modulate the cyclic AMP metabolism in 
many tissues (6). Calmodulin stimulates adenylate cyclase activity as 
well as phosphodiesterase (PDE) activity in several tissues (6-8) and 
may play a role in secretion (9). Calmodulin, therefore, could be involved 
in the increased cyclic AMP induction or abnormal calcium metabolism 
or secretion in CF fibroblasts. In order to determine whether calmodulin 
was altered in CF fibroblasts, we measured calmodulin in cultured skin 
fibroblasts from normal patients and those with CF. 
METHODS 
Fibroblasts were obtained either from the Human Genetic Mutant Cell 
Repository or from patients at the University of Michigan Hospital. The 
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cells were cultured, grown, and prepared for assay as described by 
Markovac et al. (3). The calmodulin content was determined in homog- 
enate fractions from normal and CF fibroblasts. Fibroblast cells were 
washed in Ca*’ , Mg*+ -free buffer, scraped with a rubber policeman, and 
centrifuged at 8OOg for 10 min. The cells were resuspended in 50 mM 
piperazine-N, N’-bis(Zethanesulfonic acid) (Pipes) buffer, pH 7.0, and 
sonicated for 5 min to disrupt the cells and membranes. The homogenate 
preparations were heated at 95°C for 2 min. This treatment destroys 
endogenous PDE activity but leaves calmodulin active. The calmodulin 
content in sample aliquots (5-20 kg of protein) was determined by its 
ability to activate a calmodulin-deficient brain PDE (10) using the PDE 
assay described previously (11). The calmodulin content was measured 
in nanograms using a standard curve obtained with highly purified cal- 
modulin prepared from bovine brain (12). Protein was determined by the 
method of Lowry et al. (13) using bovine serum albumin as a standard. 
PDE activity in the normal and CF fibroblasts was measured using 
concentrations of cyclic AMP of 1 and 100 PM to distinguish the high 
and low Km forms of PDE in hydrolyzing cyclic AMP. The calcium 
sensitivity of the high K,,, form was shown by the addition of 100 PM 
EGTA. 
RESULTS 
The calmodulin content in homogenate fractions of cultured skin fi- 
broblasts from 8 CF and 12 normal lines is shown in Table 1. The cells 
were grown and treated under the same conditions in which the increased 
cyclic AMP induction after metaproterenol treatment was found (3). The 
cells were always at the same stage of confluency and were presented 
blind. The data in Table 1 demonstrate that there was an overall increase 
of 60% in the calmodulin content of CF fibroblasts over normal controls. 
There is some overlap with the values for normal cells. This could partly 
reflect day to day variation in assay techniques because in any one day 
there was always a greater calmodulin content in the CF cells. The 
average CF/N ratio for each experiment was 1.6 + 0.1 SEM. This in- 
crease was significant by the Wilcoxon rank sum test at P < 0.002. 
Passage number did not affect the calmodulin content; cells were used 
from 5 to 30 passages. 
The increased induction of cyclic AMP in CF fibroblasts could be 
partially due to decreased PDE activity. Preliminary data suggest, how- 
ever, that PDE activity is not altered in the CF cells. PDE activity 
measured using 1 FM cyclic AMP was 194 + 29 pmole/min/mg protein 
in seven normal lines and 185 + 27 pmole/min/mg protein in five CF 
lines. The PDE measuring using 100 FM cyclic AMP was sensitive to 
inhibition by EGTA, a calcium chelating agent. This suggests that calcium 
296 GNEGY, ERICKSON, AND MARKOVAC 
TABLE 1 
CALMODULIN CONTENT IN FIBROBLASTS FROM CYSTIC FIBROSIS AND NORMAL CELL LINES 
Calmodulin concentration 
Cell line w (ng/p,g protein 2 SEM) 
CF Line 
GM 1957 7 1.9 5 0.2 
GM 1958 5 2.0 t 0.3 
GM 1959 4 3.1 t 0.4 
GM 0768 7 2.5 i- 0.3 
GM 770 3 2.3 2 0.1 
GM 2801 2 1.95 e 0.07 
GM 851 2 3.6 k 0.3 
GM 192 2 1.7 2 0.1 
x = 2.4 c 0.2* 
Normal Line 
872 3 1.6 + 0.1 
982 3 1.5 t 0.2 
UP-AFC 2 1.45 +- 0.2 
TB-N 2 2.2 t 0.1 
MODY-I I 1.8 
NF-B 2 1.0 
1998 2 1.45 + 0.1 
MODY-A I 0.95 
MODY-B 1 1.0 
RC-N 4 1.7 2 0.2 
NF-D 2 1.4 t 0.1 
NF-F 1 2.2 +- 
x = 1.5 2 0.1 
’ Number of determinations. 
* P < 0.002 with respect to the value for normal cells. 
and calmodulin are required for this activity. The PDE activity measured 
at 100 FM cyclic AMP was 2.08 2 0.2 nmole/min/mg protein in seven 
normal lines and 1.9 -+ 0.3 nmole/min/mg protein in five CF lines. 
DISCUSSION 
We have shown that cultured skin fibroblasts from patients with CF 
have greater calmodulin-like activity compared to those from normal 
controls. The increase in calmodulin parallels the findings of increased 
induction of cyclic AMP by P-adrenergic agonists (l-3), greater density 
of P-adrenergic receptors (3), and increased calcium concentration (4) 
found in CF fibroblasts. Thus, it seems that calmodulin is part of the 
generalized “up” regulation of the l3-adrenergic and calcium system in 
the CF fibroblasts. It is highly possible that calmodulin is contributing 
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to the increased induction of cyclic AMP in these cells as well as other 
calcium-related activities. At the present time, the function of calmodulin 
in these fibroblasts is not known. Calmodulin has been shown to stimulate 
adenylate cyclase activity in nervous tissue (6,14) in pancreatic islet cells 
(7), and chick embryo fibroblasts (8). PDE and Ca’+, Mg”-ATPase ac- 
tivities in many tissues are also stimulated by calmodulin (6). Further- 
more, a role for calmodulin has been suggested in the secretion of insulin 
(9). 
The increased calmodulin-like activity in the CF cells does not seem 
to be affecting the PDE activity even though the high K,,, PDE is most 
likely calmodulin dependent. Epstein et al. (15) found similar results for 
low K, cyclic AMP PDE activity in CF fibroblasts. Although calmodulin 
stimulates Ca”, Mg*+-ATPase activity in many cell types (6), this activity 
is decreased in CF fibroblasts (16). This is not too surprising since in- 
creased calcium levels can begin to inhibit this enzyme. It is further 
possible that the increase in calmodulin-like activity in CF cells is largely 
located in the membranes, and affects adenylate cyclase activity. For 
example, the membrane content of calmodulin is increased in the striatum 
of rats showing behavioral supersensitivity to dopamine and having in- 
creased dopamine-sensitive adenylate cyclase activity (14). 
The assay used to detect calmodulin measures calmodulin activity in 
stimulating PDE activity. Therefore the increase in calmodulin could be 
due to either an increase in calmodulin activity or in the amount of 
calmodulin. We plan to measure calmodulin using a radioimmunoassay 
that will definitely determine whether calmodulin activity or content is 
altered in CF fibroblasts. There was some overlap in the values for the 
calmodulin content in the CF fibroblasts and normal cells. This suggests 
that the alterations in this variable are not the primary gene defect in 
CF. It could, however, be related to the primary gene defect and be an 
immediate expression of the defect. Further investigation in the area 
may lead us to the primary lesion in CF. 
SUMMARY 
We have found that the content of an endogenous calcium-binding 
protein, calmodulin, is greater in cystic fibrosis fibroblasts than in normal 
cells. Homogenate preparations from CF fibroblasts contained 2.4 I~I 0.2 
ng calmodulin/~g protein while normal fibroblasts contained 1.5 2 0.1 
ng calmodulin/pg protein. Cyclic AMP phosphodiesterase activity. how- 
ever, was the same in cystic fibrosis and normal fibroblasts. The increased 
calmodulin in cystic fibrosis cells could be involved in the changes in 
calcium metabolism and cyclic AMP production found in these cells. 
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